Brief: Bellus Health Announces Positive Results From Phase 1 Bioavailability Equivalence Study

BELLUS Health

05/04/2023 12:32

April 5 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES POSITIVE RESULTS FROM ITS PHASE 1
BIOAVAILABILITY EQUIVALENCE STUDY EVALUATING ONCE-DAILY
EXTENDED-RELEASE FORMULATION OF CAMLIPIXANT IN COMPARISON TO
TWICE-DAILY IMMEDIATE RELEASE FORMULATION
    * BELLUS HEALTH INC - EXTENDED-RELEASE FORMULATION WAS WELL
TOLERATED
    * BELLUS HEALTH INC - ONCE-DAILY EXTENDED-RELEASE
FORMULATION
DEMONSTRATED EQUIVALENT BIOAVAILABILITY TO TWICE-DAILY IMMEDIATE
RELEASE FORMULATION
    * BELLUS HEALTH INC - ER FORMULATION'S SAFETY PROFILE WAS
CONSISTENT WITH PREVIOUS CAMLIPIXANT TRIALS AND NO TASTE-RELATED
ADVERSE EVENTS REPORTED

Source text for Eikon:  ID:nBw1lQprDa 
Further company coverage:  BLU.TO 

 ((reuters.briefs@thomsonreuters.com;))